INDP - Indaptus Therapeutics Inc Debt to Book Capitalization Ratio

Graphic logo of Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics ensures the continuity of biocomponent supplies by distributing production sites across safe zones. The integration of AI and robotic systems accelerates molecule development while minimizing manual labor. This chart of total debt to equity confirms financial stability, where 0.00 forms the current metric value. This enables the company to develop universal immunotherapy based on attenuated bacteria to combat tumors.

INDP (Indaptus Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of Indaptus Therapeutics Inc

Amid market volatility, investors must balance capital protection with growth potential. The stable roster of biochemists at Indaptus Therapeutics (INDP) confirms the business's internal resilience. The company's debt-to-book capitalization ratio measures the proportion of borrowed funds within the equity structure. By analyzing this debt-to-book capitalization ratio, one can assess default risk against the efficiency of leverage. An optimal indicator level ensures financial security without compromising portfolio returns.

Who Indaptus Therapeutics competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization IMNM (Immunome Corp)|GOSS: Debts to Net Assets|Debt to Book Capitalization Ratio KalVista Pharmaceuticals|septerna.com (SEPN) - Debt to Book Value Ratio|Debts to Book Capitalization Pieris Pharmaceuticals, Inc. (PVLA)|Debt to Book Value Ratio Savara Inc|Debts to Book Capitalization RIGL|Debts to Book Capitalization ANAB (AnaptysBio Inc.)|Astria Therapeutics (ATXS) - Debt to Book Capitalization Ratio|ENGN - Debts to Book Capitalization Ratio|Debt to Book Value RAPT Therapeutics, Inc. RAPT|Aerovate Therapeutics Inc (JBIO) - Debt to Book Capital|ACRS: Debt to Book Value|KYTX (Kyverna Therapeutics, Inc) - Debts to Book Capitalization|TLSA: Debt to Book Capitalization Ratio|Debts to Net Assets cabalettabio.com (CABA)|Ventyx Biosciences, Inc. (VTYX) - Debt to Book Value|Debt to Net Assets Ratio Theratechnologies, Inc. THTX|Debt to Book Value Avalo Therapeutics Inc. (AVTX)|Debt to Book Capital Eledon Pharmaceuticals, Inc ELDN|Debts to Book Capitalization Agenus (AGEN)|CLYM - Debt to Net Assets Ratio|Debts to Book Capitalization ZURA|ATYR (aTyr Pharma Inc) - Debts to Book Value|ADAG - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Ikena Oncology, Inc.|Debts to Book Capitalization STTK|Debts to Book Capitalization EQ (equilliumbio.com)|Connect Biopharma Holdings Limited (CNTB) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Immunic Therapeutics IMUX|ATRA (Atara Biotherapeutics Inc) - Debts to Book Capitalization|InflaRx N.V. (IFRX) - Debts to Book Value|XFOR: Debt to Book Value|Debts to Book Capitalization Adicet Bio, Inc.|Celularity Inc (CELU) - Debt to Book Value|Debt to Book Capital INmune Bio Inc|BRNS (Barinthus Bio) - Debts to Book Capitalization|Debts to Net Assets Kezar Life Sciences Inc (KZR)|SAB Biotherapeutics - Debts to Book Capitalization|akaritx.com - Debt to Book Value|Debt to Book Capitalization Ratio ENLV (Enlivex Therapeutics, Ltd.)|QTTB - Debts to Net Assets|GeoVax Labs Inc - Debts to Book Capitalization|EDSA (Edesa Biotech Corp) - Debts to Net Assets|Debt to Book Capitalization Ratio iBio, Inc. (IBIO)|Debt to Book Value Ratio Carisma Tx|Debts to Book Capitalization XTL Biopharmaceuticals Ltd. XTLB|Debt to Book Value Ratio BOLT (boltbio.com)|HCW Biologics (HCWB) - Debt to Book Capitalization Ratio|Aptevo Therapeutics, Inc. - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio AIM ImmunoTech|ADTX - Debts to Book Capitalization Ratio|Debts to Book Capitalization GRI Bio GRI|XORTX Therapeutics Inc (XRTX) - Debt to Net Assets Ratio|HIND (ReShape Lifesciences) - Debts to Book Capitalization|Debts to Book Capitalization REVB|Scinai Immunotherapeutics (SCNI) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CALI (calcimedica.com)|Affimed N.V. - Debt to Book Capitalization Ratio|Debt to Book Value Allakos Inc ALLK|HOOKIPA - Debts to Book Capitalization|IGM Biosciences, Inc. (IGMS) - Debts to Book Capitalization|Debt to Book Value iTeos Therapeutics ITOS|oceanbiomedical.com (OCEA) - Debt to Net Assets Ratio|TCBP: Debts to Book Capitalization|Debts to Net Assets THRD